Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, uncontrolled, multi-center phase II study to investigate efficacy and safety of ONO-4538 in patients with uterine cervical cancer, uterine corpus cancer, and soft-tissue sarcoma

Trial Profile

An open-label, uncontrolled, multi-center phase II study to investigate efficacy and safety of ONO-4538 in patients with uterine cervical cancer, uterine corpus cancer, and soft-tissue sarcoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Cervical cancer; Soft tissue sarcoma; Uterine cancer
  • Focus Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 01 Sep 2019 Results published in the Cancer Science
    • 05 Jun 2018 Primary endpoint (Overall response rate in patients with advanced or recurrent uterine cervical or corpus cancer) has been met.
    • 05 Jun 2018 Results (n=43) assessing efficacy and safety of nivolumab in patients with advanced or recurrent uterine cervical or corpus cancer, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top